XML 28 R15.htm IDEA: XBRL DOCUMENT
v3.4.0.3

Goodwill and Intangible Assets | 3 Months Ended
--- | ---
Mar. 31, 2016
Goodwill and Intangible Assets |
Goodwill and Intangible Assets | 9. Goodwill and Intangible Assets Intangible assets include product rights, trademarks, patents, land-use rights, and goodwill. The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification:
|  | Weighted-Average |  |  |  |  | Accumulated |  |  |  |
|  | Life (Years) |  | Original Cost |  | Amortization |  | Net Book Value |
|  | (in thousands) |
Definite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Product rights |  | 12 |  | $ | 27,134 |  | $ | 23,124 |  | $ | 4,010 |
Patents |  | 10 |  |  | 293 |  |  | 115 |  |  | 178 |
Trademarks |  | 11 |  |  | 15 |  |  | 15 |  |  | — |
Land-use rights |  | 39 |  |  | 2,540 |  |  | 304 |  |  | 2,236 |
Acquired ANDAs(1) |  | * |  |  | 4,000 |  |  | — |  |  | 4,000 |
Other intangible assets |  | 1 |  |  | 575 |  |  | 521 |  |  | 54 |
Subtotal |  | 12 |  |  | 34,557 |  |  | 24,079 |  |  | 10,478 |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Trademark |  | * |  |  | 29,225 |  |  | — |  |  | 29,225 |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |
Finished pharmaceutical products |  | * |  |  | 4,321 |  |  | — |  |  | 4,321 |
Subtotal |  | * |  |  | 33,546 |  |  | — |  |  | 33,546 |
As of March 31, 2016 |  | * |  | $ | 68,103 |  | $ | 24,079 |  | $ | 44,024 |
|  | Weighted-Average |  |  |  |  | Accumulated |  |  |  |
|  | Life (Years) |  | Original Cost |  | Amortization |  | Net Book Value |
|  | (in thousands) |
Definite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Product rights |  | 12 |  | $ | 27,134 |  | $ | 22,679 |  | $ | 4,455 |
Patents |  | 10 |  |  | 293 |  |  | 107 |  |  | 186 |
Trademarks |  | 11 |  |  | 15 |  |  | 15 |  |  | — |
Land-use rights |  | 39 |  |  | 2,540 |  |  | 288 |  |  | 2,252 |
Other intangible assets |  | 1 |  |  | 590 |  |  | 533 |  |  | 57 |
Subtotal |  | 12 |  |  | 30,572 |  |  | 23,622 |  |  | 6,950 |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Trademark |  | * |  |  | 29,225 |  |  | — |  |  | 29,225 |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |
Finished pharmaceutical products |  | * |  |  | 3,726 |  |  | — |  |  | 3,726 |
Subtotal |  | * |  |  | 32,951 |  |  | — |  |  | 32,951 |
As of December 31, 2015 |  | * |  | $ | 63,523 |  | $ | 23,622 |  | $ | 39,901 |
*Intangible assets with indefinite lives have an indeterminable average life. (1)In March 2016, the Company acquired fourteen ANDAs representing eleven different injectable chemical entities from Hikma Pharmaceuticals PLC for $4.0 million. As a result, the accounting and determination of the life of the intangible asset has yet to be determined. (See note 3). Goodwill The changes in the carrying amounts of goodwill were as follows:
|  | March 31, |  | December 31, |
|  | 2016 |  | 2015 |
|  | (in thousands) |
Beginning balance |  | $ | 3,726 |  | $ | 4,467 |
Goodwill related to acquisition of business |  |  | 444 |  |  | — |
Currency translation and other adjustments |  |  | 151 |  |  | (741) |
Ending balance |  | $ | 4,321 |  | $ | 3,726 |
Primatene® Trademark In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene® Mist, an over-the-counter bronchodilator product, for a total consideration of $29.2 million, which is its carrying value as of March 31, 2016. In determining the useful life of the trademark, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors. As a result of environmental concerns about Chlorofluorocarbons, or CFCs, the FDA issued a final ruling on January 16, 2009 that required the CFC formulation of its Primatene® Mist product to be phased out by December 31, 2011. The former formulation of Primatene® Mist contained CFCs as a propellant; however, the Company intends to use the trademark for a future version of Primatene® that utilizes hydrofluoroalkane, or HFA, as a propellant. In 2013, the Company filed a new drug application, or NDA, for Primatene® HFA and received a Prescription Drug User Fee Act date set for May 2014. In May 2014, the Company received a complete response letter, or CRL, from the FDA, which requires additional non-clinical information, label revisions and follow-up studies (label comprehension, behavioral/human factors and actual use) to assess consumers’ ability to use the device correctly to support approval of the product in the over-the-counter setting. The Company met with the FDA in October 2014 to discuss preliminary data results and to clarify the FDA requirements for further studies. The Company received further advice regarding its ongoing studies from the FDA in January 2016 and is currently in the process of generating the remaining data required by the CRL and plans to submit an NDA amendment that it believes will address the FDA’s concerns. However, there can be no guarantee that any amendment to the Company’s NDA will result in timely approval of the product or approval at all. Based on the Company’s filed version of Primatene® HFA, the Company’s plan to respond to the CRL to address the FDA’s concerns, the long history of the Primatene® trademark (marketed since 1963) and the Company’s perpetual rights to the trademark, the Company has determined that the trademark has an indefinite useful life. If the HFA version is approved by the FDA, it will be marketed under the same trade name; therefore, an impairment charge would not be required.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration